Expression of CD Markers in JAK2 Positive Myeloproliferative Neoplasms: Prognostic Significance

Overview

Journal Oncol Rev

Specialty Oncology

Date 2018 Nov 9

PMID 30405895

Citations 3

Authors

Saeid Shahrabi

Ali Ehsanpour

Somayyeh Heidary

Mohammad Shahjahani

Masumeh Maleki Behzad

Affiliations

Soon will be listed here.

Abstract

Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by the presence of JAK2 mutation. Thrombohemorrhagic as well as autoimmune or inflammatory phenomena are common clinical outcomes of these disorders. Recent studies have shown that abnormality in frequency and function of blood cells manifested by an alteration in CD markers' expression patterns play a key role in these complications. So, there may be a relationship between CD markers' expressions and prognosis of JAK2 positive MPNs. Therefore, in this review, we have focused on these abnormalities from the perspective of changing expressions of CD markers and assessment of the relationship between these changes with prognosis of JAK2 positive MPNs. It can be stated that the abnormal expression of a large number of CD markers can be used as a prognostic biomarker for clinical outcomes including thrombohememorrhagic events, as well as autoimmune and leukemic transformation in JAK2 positive MPNs. Considering the possible role of CD markers' expressions in JAK2 MPNs prognosis, further studies are needed to confirm the relationship between the expression of CD markers with prognosis to be able to find an appropriate therapeutic approach via targeting CD markers.

Citing Articles

Spatial Mapping of Hematopoietic Clones in Human Bone Marrow.

Young A, Davis H, Cox M, Parsons T, Burkart S, Bender D Blood Cancer Discov. 2024; 5(3):153-163.

PMID: 38421682 PMC: 11062237. DOI: 10.1158/2643-3230.BCD-23-0110.

Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Stuckey R, Gomez-Casares M Int J Mol Sci. 2021; 22(9).

PMID: 34068690 PMC: 8126083. DOI: 10.3390/ijms22095042.

CD markers polymorphisms as prognostic biomarkers in hematological malignancies.

Shahrabi S, Ghanavat M, Maleki Behzad M, Purrahman D, Saki N Oncol Rev. 2020; 14(2):466.

PMID: 32782727 PMC: 7385526. DOI: 10.4081/oncol.2020.466.

References

Pardanani A, Lasho T, Finke C, Mesa R, Hogan W, Ketterling R . Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells. 2007; 25(9):2358-62. DOI: 10.1634/stemcells.2007-0175. View

Li J, Xia Y, Kuter D . The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br J Haematol. 2000; 111(3):943-53. View

Barosi G, Bergamaschi G, Marchetti M, Vannucchi A, Guglielmelli P, Antonioli E . JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007; 110(12):4030-6. DOI: 10.1182/blood-2007-07-099184. View

Barbui T . The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?. Semin Hematol. 2004; 41(2 Suppl 3):15-7. DOI: 10.1053/j.seminhematol.2004.02.006. View

Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H . PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol. 2004; 83(6):364-70. DOI: 10.1007/s00277-004-0864-9. View

Falanga A, Marchetti M . Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012; 2012:571-81. DOI: 10.1182/asheducation-2012.1.571. View

Gohring K, Wolff J, Doppl W, Schmidt K, Fenchel K, Pralle H . Neutrophil CD177 (NB1 gp, HNA-2a) expression is increased in severe bacterial infections and polycythaemia vera. Br J Haematol. 2004; 126(2):252-4. DOI: 10.1111/j.1365-2141.2004.05027.x. View

Tabaczewski P, Nadesan S, Lim S . Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell?. Leuk Res. 2008; 33(6):854-5. PMC: 2695994. DOI: 10.1016/j.leukres.2008.09.002. View

Levine R, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4):387-97. DOI: 10.1016/j.ccr.2005.03.023. View

10.

Arellano-Rodrigo E, Alvarez-Larran A, Reverter J, Colomer D, Villamor N, Bellosillo B . Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2008; 84(2):102-8. DOI: 10.1002/ajh.21338. View

11.

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y . Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010; 116(19):3735-42. DOI: 10.1182/blood-2010-03-274811. View

12.

Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T . Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005; 33(5):523-30. DOI: 10.1016/j.exphem.2005.01.015. View

13.

Bruchova H, Yoon D, Agarwal A, Swierczek S, Prchal J . Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis. 2009; 43(1):81-7. PMC: 2693444. DOI: 10.1016/j.bcmd.2009.02.001. View

14.

Riley C, Jensen M, Brimnes M, Hasselbalch H, Bjerrum O, Straten P . Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood. 2011; 118(8):2170-3. DOI: 10.1182/blood-2011-03-340992. View

15.

Riley C, Brimnes M, Hansen M, Jensen M, Hasselbalch H, Kjaer L . Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur J Haematol. 2015; 97(1):83-92. DOI: 10.1111/ejh.12687. View

16.

Ishii T, Bruno E, Hoffman R, Xu M . Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006; 108(9):3128-34. DOI: 10.1182/blood-2006-04-017392. View

17.

Trelinski J, Wierzbowska A, Krawczynska A, Sakowicz A, Pietrucha T, Smolewski P . Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. Int J Hematol. 2010; 91(5):792-8. DOI: 10.1007/s12185-010-0596-7. View

18.

Cooper M, Fehniger T, Turner S, Chen K, Ghaheri B, Ghayur T . Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001; 97(10):3146-51. DOI: 10.1182/blood.v97.10.3146. View

19.

Ohanian M, Bueso-Ramos C, Ok C, Lin P, Patel K, Alattar M . Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015; 208(11):571-4. PMC: 4835801. DOI: 10.1016/j.cancergen.2015.06.004. View

20.

Delhommeau F, Dupont S, Tonetti C, Masse A, Godin I, Le Couedic J . Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2006; 109(1):71-7. DOI: 10.1182/blood-2006-03-007146. View